As originally reported in Mass High Tech, Immunetics Inc., a Boston diagnostics company that develops tests for infectious diseases and blood screening, has received $629,000 in equity out of a $750,000 offering for the commercialization of a blood platelet contamination tester for hospitals and blood banks.
Founder, CEO, and Scientific Director Andrew Levin said the money will go toward commercializing its test for bacterial contamination of blood platelets, BacTx Bacterial Detection Kit
, which was cleared by FDA in June.
“Platelets are essential to blood clotting, but have a high risk of bacterial contamination,” said Levin, adding that the risk is “orders of magnitude” higher than the risk of blood to be used for transfusion being contaminated by, say, HIV.
Immunetics researches, develops, manufactures and markets diagnostic products for bacterial, viral and parasitic diseases, including Lyme disease and HIV. Products are manufactured at the company’s headquarters in the Seaport District of Boston. International business in markets such as Europe, Africa, Mexico, Canada, and India account for 40% of the company’s total sales.